What is FAPI PET Scan?
FAPI PET scan is an advanced molecular imaging technique that uses radiolabeled fibroblast activation protein inhibitors (typically ⁶⁸Ga-FAPI or ¹⁸F-FAPI) to visualize cancer-associated fibroblasts and activated fibroblasts in the tumor microenvironment, offering superior tumor detection compared to traditional FDG-PET in many cancer types, particularly those with low metabolic activity. 1, 2
How FAPI PET Works
FAPI PET targets fibroblast activation protein (FAP), a serine protease that is:
- Selectively overexpressed in cancer-associated fibroblasts (CAFs) surrounding tumors
- Present in fibrotic tissues and areas of active tissue remodeling
- Largely absent in normal tissues, providing excellent tumor-to-background contrast 1, 3
Unlike ¹⁸F-FDG PET which images glucose metabolism in tumor cells themselves, FAPI PET images the tumor microenvironment - specifically the stromal component that supports tumor growth 2.
Key Technical Advantages
FAPI PET offers several imaging benefits:
- Rapid tumor accumulation with high tumor-to-background ratios
- Low background uptake in normal tissues (particularly brain, liver, and muscles)
- Fast clearance from blood and normal organs
- Superior image quality within 1 hour of injection 1, 3
Clinical Applications
Oncology (Primary Use)
FAPI PET demonstrates excellent performance across diverse malignancies, particularly excelling in cancers that show poor FDG uptake:
- Pancreatic cancer
- Cholangiocarcinoma
- Certain sarcomas
- Lung tumors (sensitivity 0.99, specificity 0.82) 4
- Various other solid tumors with low glycolytic activity 1, 5
The imaging enables:
- Improved tumor delineation and staging (lung tumor staging sensitivity: 0.93) 4
- Better detection of lesions inconclusive on FDG-PET
- Enhanced response assessment 1, 6
Non-Oncologic Applications
FAPI PET shows promise in fibrotic and inflammatory conditions:
Cardiovascular disease:
- Myocardial fibrosis detection
- Post-myocardial infarction remodeling
- Hypertrophic cardiomyopathy
- Heart failure assessment 1
Pulmonary disease:
- Idiopathic pulmonary fibrosis (IPF) - sensitivity 1.00 4
- Pneumonia assessment (sensitivity 0.80, specificity 0.90) 4
- Other interstitial lung diseases 6, 4
Inflammatory myopathy:
- Correlates with muscle edema and disease activity
- Useful for evaluating idiopathic inflammatory myopathy (IIM) 7
Current Clinical Status
Important Limitations
According to 2023 EANM guidelines, FAPI PET is NOT currently recommended for routine clinical use in hematological malignancies:
- Expert consensus disagrees with using FAPI-PET for staging Hodgkin or high-grade non-Hodgkin lymphoma instead of FDG-PET 8
- Expert consensus disagrees with using FAPI-PET for staging low-grade non-Hodgkin lymphoma 8
- Expert consensus disagrees with using FAPI-PET to drive FAPI-based therapy in refractory patients 8
Evidence Base
The current literature consists primarily of:
Large-scale prospective trials and standardized protocols are still needed before FAPI PET enters clinical guidelines 1, 2.
Theranostic Potential
A major advantage of FAPI is its theranostic capability - the same FAP-targeting molecule can be labeled with:
- Diagnostic radionuclides (⁶⁸Ga, ¹⁸F) for PET imaging
- Therapeutic radionuclides (⁹⁰Y, ¹⁷⁷Lu) for targeted radionuclide therapy
This positions FAPI as a key tool in precision oncology, allowing imaging to guide subsequent targeted therapy 1, 3.
Clinical Pitfalls
Physiologic uptake patterns must be understood to avoid false positives:
- FAPI uptake occurs in wound healing sites
- Active inflammatory processes show uptake
- Benign fibrotic conditions demonstrate tracer accumulation 5, 3
Accurate interpretation requires distinguishing between malignant and benign causes of FAP expression, particularly in inflammatory and fibrotic conditions 5.